Figure 2.

Cumulative IOP difference and peak contrast sensitivity loss after bead injection. (A) Cumulative IOP difference of bead-injected eyes was increased across the entire range of the study (beads, green) and was attenuated by both brinzolamide (orange) and brimonidine (purple). A post hoc analysis revealed that only brinzolamide-treated animals had a statistically significant decrease in cumulative IOP difference compared with animals that did not receive IOP-lowering drops (1-way ANOVA, Bonferroni post hoc; P = 0.041; bracket with #). While brimonidine treatment trended toward lowering IOP, this effect was not significant compared with animals that did not receive IOP-lowering drops (Bonferroni post hoc: P = 0.184; n = 17 for beads only, 9 for brinzolamide, and 12 for brimonidine). (B, C) Contrast sensitivity loss was observed under both photopic (B) and scotopic (C) conditions in animals that received a unilateral bead injection but not IOP-lowering eye drops (green). While brinzolamide treatment (orange) attenuated this contrast sensitivity loss in both lighting conditions, it only resulted in a significant difference compared with animals that did not receive treatment in scotopic conditions (ANOVA, Bonferroni post hoc: photopic, P = 0.159; scotopic, P = 0.002; bracket with #). Brimonidine (purple) attenuated the contrast sensitivity loss even further and resulted in contrast sensitivity loss that was statistically smaller than the loss observed in bead-treated animals in both light intensities (ANOVA, Bonferroni post hoc: P < 0.001 for both photopic and scotopic; brackets with ^; none, n = 7; brinzolamide, n = 9; brimonidine, n = 7). Mean ± SEM is shown for all panels.